{"podcast":{"title":"Decera Clinical Education Oncology Podcast","slug":"decera-clinical-education-oncology-podcast-1302999","podcast_index_feed_id":1302999,"rss_url":"https://feeds.simplecast.com/GlfUTtJq","website_url":"https://oncologypodcast.simplecast.com","image_url":"https://image.simplecastcdn.com/images/ec61b327-3a4f-4bed-a4d2-7c7d2df62891/2d9bf1a9-d5c4-4079-9b3e-a531bfcf7774/3000x3000/decera-onc-podcast-show-icon.jpg?aid=rss_feed","author":"Decera Clinical Education","episode_count":253,"summary":"Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Decera Clinical Education. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.","last_synced_at":"2026-07-15T02:18:52.844818+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999"},"episodes":[{"title":"Beyond BCMA: How GPRC5D-Targeted Therapy Fits Iinto Multiple Myeloma Care Today","slug":"beyond-bcma-how-gprc5d-targeted-therapy-fits-iinto-multiple-myeloma-care-today","published_at":"2026-07-14T13:12:51+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/beyond-bcma-how-gprc5d-targeted-therapy-fits-iinto-multiple-myeloma-care-today","url":"https://oncologypodcast.simplecast.com/episodes/beyond-bcma-how-gprc5d-targeted-therapy-fits-iinto-multiple-myeloma-care-today-28PTkCp1","duration_seconds":1614,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/beyond-bcma-how-gprc5d-targeted-therapy-fits-iinto-multiple-myeloma-care-today/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/beyond-bcma-how-gprc5d-targeted-therapy-fits-iinto-multiple-myeloma-care-today.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"What Oncology Pharmacists Need to Know About Targeting BCMA in Early Relapsed/Refractory Myeloma","slug":"what-oncology-pharmacists-need-to-know-about-targeting-bcma-in-early-relapsed-refractory-myeloma","published_at":"2026-07-13T19:28:33+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/what-oncology-pharmacists-need-to-know-about-targeting-bcma-in-early-relapsed-refractory-myeloma","url":"https://oncologypodcast.simplecast.com/episodes/what-oncology-pharmacists-need-to-know-about-targeting-bcma-in-early-relapsed-refractory-myeloma-LttbW4Ku","duration_seconds":1713,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/what-oncology-pharmacists-need-to-know-about-targeting-bcma-in-early-relapsed-refractory-myeloma/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/what-oncology-pharmacists-need-to-know-about-targeting-bcma-in-early-relapsed-refractory-myeloma.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Incorporating AKT1 and PIK3CA Pathway Testing and Targeted Therapies in the Management of Advanced Endocrine-Resistant Breast Cancer","slug":"incorporating-akt1-and-pik3ca-pathway-testing-and-targeted-therapies-in-the-management-of-advanced-endocrine-resistant-breast-cancer","published_at":"2026-06-30T18:57:34+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/incorporating-akt1-and-pik3ca-pathway-testing-and-targeted-therapies-in-the-management-of-advanced-endocrine-resistant-breast-cancer","url":"https://oncologypodcast.simplecast.com/episodes/incorporating-akt1-and-pik3ca-pathway-testing-and-targeted-therapies-in-the-management-of-advanced-endocrine-resistant-breast-cancer-9JQWI05_","duration_seconds":1444,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/incorporating-akt1-and-pik3ca-pathway-testing-and-targeted-therapies-in-the-management-of-advanced-endocrine-resistant-breast-cancer/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/incorporating-akt1-and-pik3ca-pathway-testing-and-targeted-therapies-in-the-management-of-advanced-endocrine-resistant-breast-cancer.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Personalizing EGFR Mutation–Positive NSCLC Care: Strategies for the Advanced Practice Provider","slug":"personalizing-egfr-mutation-positive-nsclc-care-strategies-for-the-advanced-practice-provider","published_at":"2026-06-22T15:16:16+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/personalizing-egfr-mutation-positive-nsclc-care-strategies-for-the-advanced-practice-provider","url":"https://oncologypodcast.simplecast.com/episodes/personalizing-egfr-mutationpositive-nsclc-care-strategies-for-the-advanced-practice-provider-GgoiZkZE","duration_seconds":1618,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/personalizing-egfr-mutation-positive-nsclc-care-strategies-for-the-advanced-practice-provider/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/personalizing-egfr-mutation-positive-nsclc-care-strategies-for-the-advanced-practice-provider.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Advancing the Early Detection of Lung Cancer: Expanding Screening Access, Eligibility, and Awareness","slug":"advancing-the-early-detection-of-lung-cancer-expanding-screening-access-eligibility-and-awareness","published_at":"2026-06-09T17:23:16+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/advancing-the-early-detection-of-lung-cancer-expanding-screening-access-eligibility-and-awareness","url":"https://oncologypodcast.simplecast.com/episodes/advancing-the-early-detection-of-lung-cancer-expanding-screening-access-eligibility-and-awareness-bAIF42zm","duration_seconds":1643,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/advancing-the-early-detection-of-lung-cancer-expanding-screening-access-eligibility-and-awareness/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/advancing-the-early-detection-of-lung-cancer-expanding-screening-access-eligibility-and-awareness.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"HNSCC: Current and Emerging Therapeutic Strategies","slug":"hnscc-current-and-emerging-therapeutic-strategies","published_at":"2026-05-29T21:01:30+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/hnscc-current-and-emerging-therapeutic-strategies","url":"https://oncologypodcast.simplecast.com/episodes/hnscc-current-and-emerging-therapeutic-strategies-S2rr8GIO","duration_seconds":1584,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/hnscc-current-and-emerging-therapeutic-strategies/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/hnscc-current-and-emerging-therapeutic-strategies.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Navigating Relapsed/Refractory Multiple Myeloma: Real-world Use of Bispecific Antibodies","slug":"navigating-relapsed-refractory-multiple-myeloma-real-world-use-of-bispecific-antibodies","published_at":"2026-05-15T19:36:02+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/navigating-relapsed-refractory-multiple-myeloma-real-world-use-of-bispecific-antibodies","url":"https://oncologypodcast.simplecast.com/episodes/navigating-relapsed-refractory-multiple-myeloma-real-world-use-of-bispecific-antibodies-Pcp0ZYXd","duration_seconds":1250,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/navigating-relapsed-refractory-multiple-myeloma-real-world-use-of-bispecific-antibodies/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/navigating-relapsed-refractory-multiple-myeloma-real-world-use-of-bispecific-antibodies.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Oncologists “On Call”: Our Practical Experiences to Optimizing Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma","slug":"oncologists-on-call-our-practical-experiences-to-optimizing-bispecific-antibody-therapy-in-relapsed-refractory-multiple-myeloma","published_at":"2026-05-07T13:14:37+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/oncologists-on-call-our-practical-experiences-to-optimizing-bispecific-antibody-therapy-in-relapsed-refractory-multiple-myeloma","url":"https://oncologypodcast.simplecast.com/episodes/oncologists-on-call-our-practical-experiences-to-optimizing-bispecific-antibody-therapy-in-relapsed-refractory-multiple-myeloma-g4ris29j","duration_seconds":1860,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/oncologists-on-call-our-practical-experiences-to-optimizing-bispecific-antibody-therapy-in-relapsed-refractory-multiple-myeloma/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/oncologists-on-call-our-practical-experiences-to-optimizing-bispecific-antibody-therapy-in-relapsed-refractory-multiple-myeloma.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Thrombotic Events and ET/PV: What You Should Know","slug":"thrombotic-events-and-et-pv-what-you-should-know","published_at":"2026-04-30T20:15:58+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/thrombotic-events-and-et-pv-what-you-should-know","url":"https://oncologypodcast.simplecast.com/episodes/thrombotic-events-and-et-pv-what-you-should-know-6D48J6yQ","duration_seconds":1328,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/thrombotic-events-and-et-pv-what-you-should-know/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/thrombotic-events-and-et-pv-what-you-should-know.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Global Experts Discuss Current and Emerging Treatments for ET and PV","slug":"global-experts-discuss-current-and-emerging-treatments-for-et-and-pv","published_at":"2026-04-30T20:08:16+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/global-experts-discuss-current-and-emerging-treatments-for-et-and-pv","url":"https://oncologypodcast.simplecast.com/episodes/global-experts-discuss-current-and-emerging-treatments-for-et-and-pv-wRmT4_Kk","duration_seconds":1041,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/global-experts-discuss-current-and-emerging-treatments-for-et-and-pv/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/global-experts-discuss-current-and-emerging-treatments-for-et-and-pv.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Global Experts Discuss Diagnostic Considerations in ET and PV","slug":"global-experts-discuss-diagnostic-considerations-in-et-and-pv","published_at":"2026-04-29T20:02:34+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/global-experts-discuss-diagnostic-considerations-in-et-and-pv","url":"https://oncologypodcast.simplecast.com/episodes/global-experts-discuss-diagnostic-considerations-in-et-and-pv-AUpIdd4q","duration_seconds":895,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/global-experts-discuss-diagnostic-considerations-in-et-and-pv/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/global-experts-discuss-diagnostic-considerations-in-et-and-pv.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Experts Discuss Novel Approaches to First-line Therapy for HER2-Positive Metastatic Breast Cancer","slug":"experts-discuss-novel-approaches-to-first-line-therapy-for-her2-positive-metastatic-breast-cancer","published_at":"2026-04-17T18:05:54+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/experts-discuss-novel-approaches-to-first-line-therapy-for-her2-positive-metastatic-breast-cancer","url":"https://oncologypodcast.simplecast.com/episodes/experts-discuss-novel-approaches-to-first-line-therapy-for-her2-positive-metastatic-breast-cancer-nzA_gF1n","duration_seconds":1361,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/experts-discuss-novel-approaches-to-first-line-therapy-for-her2-positive-metastatic-breast-cancer/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/experts-discuss-novel-approaches-to-first-line-therapy-for-her2-positive-metastatic-breast-cancer.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Patient Voices: Caring for the Whole Patient and Personalizing Treatment of Early Breast Cancer to Achieve Equitable Outcomes","slug":"patient-voices-caring-for-the-whole-patient-and-personalizing-treatment-of-early-breast-cancer-to-achieve-equitable-outcomes","published_at":"2026-04-15T20:55:22+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/patient-voices-caring-for-the-whole-patient-and-personalizing-treatment-of-early-breast-cancer-to-achieve-equitable-outcomes","url":"https://oncologypodcast.simplecast.com/episodes/patient-voices-early-breast-cancer-GQRwO3ua","duration_seconds":2502,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/patient-voices-caring-for-the-whole-patient-and-personalizing-treatment-of-early-breast-cancer-to-achieve-equitable-outcomes/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/patient-voices-caring-for-the-whole-patient-and-personalizing-treatment-of-early-breast-cancer-to-achieve-equitable-outcomes.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities","slug":"role-of-akt-and-pi3k-inhibitors-in-patients-with-hr-positive-breast-cancers-experts-share-their-thoughts-on-current-practice-and-future-opportunities","published_at":"2026-04-15T17:57:46+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/role-of-akt-and-pi3k-inhibitors-in-patients-with-hr-positive-breast-cancers-experts-share-their-thoughts-on-current-practice-and-future-opportunities","url":"https://oncologypodcast.simplecast.com/episodes/akt-and-pi3k-inhibitors-breast-cancer-SqsGu6ru","duration_seconds":1882,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/role-of-akt-and-pi3k-inhibitors-in-patients-with-hr-positive-breast-cancers-experts-share-their-thoughts-on-current-practice-and-future-opportunities/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/role-of-akt-and-pi3k-inhibitors-in-patients-with-hr-positive-breast-cancers-experts-share-their-thoughts-on-current-practice-and-future-opportunities.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Patient-Centered Management of CDK4/6 Inhibitor Therapy: Adverse Event Mitigation, Adherence, and Persistence in HR+/HER2- Breast Cancer","slug":"patient-centered-management-of-cdk4-6-inhibitor-therapy-adverse-event-mitigation-adherence-and-persistence-in-hr-her2-breast-cancer","published_at":"2026-04-14T19:56:16+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/patient-centered-management-of-cdk4-6-inhibitor-therapy-adverse-event-mitigation-adherence-and-persistence-in-hr-her2-breast-cancer","url":"https://oncologypodcast.simplecast.com/episodes/patient-centered-management-of-cdk4-6-inhibitor-therapy-adverse-event-mitigation-adherence-and-persistence-in-hr-her2-breast-cancer-pCssUC_H","duration_seconds":2686,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/patient-centered-management-of-cdk4-6-inhibitor-therapy-adverse-event-mitigation-adherence-and-persistence-in-hr-her2-breast-cancer/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/patient-centered-management-of-cdk4-6-inhibitor-therapy-adverse-event-mitigation-adherence-and-persistence-in-hr-her2-breast-cancer.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"TROP2-Directed Antibody–Drug Conjugates in Non-Small-Cell Lung Cancer: Current Use in Clinical Practice and Future Directions","slug":"trop2-directed-antibody-drug-conjugates-in-non-small-cell-lung-cancer-current-use-in-clinical-practice-and-future-directions","published_at":"2026-04-13T15:40:27+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/trop2-directed-antibody-drug-conjugates-in-non-small-cell-lung-cancer-current-use-in-clinical-practice-and-future-directions","url":"https://oncologypodcast.simplecast.com/episodes/trop2-directed-antibodydrug-conjugates-in-non-small-cell-lung-cancer-current-use-in-clinical-practice-and-future-directions-c_sZINJs","duration_seconds":1993,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/trop2-directed-antibody-drug-conjugates-in-non-small-cell-lung-cancer-current-use-in-clinical-practice-and-future-directions/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/trop2-directed-antibody-drug-conjugates-in-non-small-cell-lung-cancer-current-use-in-clinical-practice-and-future-directions.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Emerging Therapies for Patients With HER2+ Gastroesophageal Adenocarcinoma and Biliary Tract Cancer","slug":"emerging-therapies-for-patients-with-her2-gastroesophageal-adenocarcinoma-and-biliary-tract-cancer","published_at":"2026-04-13T15:01:24+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/emerging-therapies-for-patients-with-her2-gastroesophageal-adenocarcinoma-and-biliary-tract-cancer","url":"https://oncologypodcast.simplecast.com/episodes/emerging-therapies-for-patients-with-her2-gastroesophageal-adenocarcinoma-and-biliary-tract-cancer-eZiHgaHf","duration_seconds":2352,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/emerging-therapies-for-patients-with-her2-gastroesophageal-adenocarcinoma-and-biliary-tract-cancer/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/emerging-therapies-for-patients-with-her2-gastroesophageal-adenocarcinoma-and-biliary-tract-cancer.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Experts Discuss ADCs for HER2-Negative/Ultralow/Low MBC","slug":"experts-discuss-adcs-for-her2-negative-ultralow-low-mbc","published_at":"2026-03-26T13:13:16+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/experts-discuss-adcs-for-her2-negative-ultralow-low-mbc","url":"https://oncologypodcast.simplecast.com/episodes/experts-discuss-adcs-for-her2-negative-ultralow-low-mbc-rXxfzGFZ","duration_seconds":1156,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/experts-discuss-adcs-for-her2-negative-ultralow-low-mbc/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/experts-discuss-adcs-for-her2-negative-ultralow-low-mbc.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Colorectal Cancer","slug":"advanced-practice-professionals-on-biomarker-testing-in-patients-with-solid-tumors-colorectal-cancer","published_at":"2026-03-25T20:46:41+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/advanced-practice-professionals-on-biomarker-testing-in-patients-with-solid-tumors-colorectal-cancer","url":"https://oncologypodcast.simplecast.com/episodes/advanced-practice-professionals-on-biomarker-testing-in-patients-with-solid-tumors-colorectal-cancer-H9QtAE7a","duration_seconds":2003,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/advanced-practice-professionals-on-biomarker-testing-in-patients-with-solid-tumors-colorectal-cancer/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/advanced-practice-professionals-on-biomarker-testing-in-patients-with-solid-tumors-colorectal-cancer.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Advanced Practice Professionals on Biomarker Testing in Patients With Solid Tumors: Prostate Cancer","slug":"advanced-practice-professionals-on-biomarker-testing-in-patients-with-solid-tumors-prostate-cancer","published_at":"2026-03-25T14:06:13+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/advanced-practice-professionals-on-biomarker-testing-in-patients-with-solid-tumors-prostate-cancer","url":"https://oncologypodcast.simplecast.com/episodes/advanced-practice-professionals-on-biomarker-testing-in-patients-with-solid-tumors-prostate-cancer-gPEubEaL","duration_seconds":1339,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/advanced-practice-professionals-on-biomarker-testing-in-patients-with-solid-tumors-prostate-cancer/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/advanced-practice-professionals-on-biomarker-testing-in-patients-with-solid-tumors-prostate-cancer.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Bladder Cancer Breakthroughs: New NMIBC Therapies and EV + Pembrolizumab Updates From ASCO GU 2026","slug":"bladder-cancer-breakthroughs-new-nmibc-therapies-and-ev-pembrolizumab-updates-from-asco-gu-2026","published_at":"2026-03-23T19:19:56+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/bladder-cancer-breakthroughs-new-nmibc-therapies-and-ev-pembrolizumab-updates-from-asco-gu-2026","url":"https://oncologypodcast.simplecast.com/episodes/bladder-cancer-breakthroughs-new-nmibc-therapies-and-ev-pembrolizumab-updates-from-asco-gu-2026-VT2A9cW5","duration_seconds":1137,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/bladder-cancer-breakthroughs-new-nmibc-therapies-and-ev-pembrolizumab-updates-from-asco-gu-2026/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/bladder-cancer-breakthroughs-new-nmibc-therapies-and-ev-pembrolizumab-updates-from-asco-gu-2026.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Myth vs Medicine: Pharmacist’s Perspective on Adjuvant CDK4/6 Inhibitor Optimization","slug":"myth-vs-medicine-pharmacist-s-perspective-on-adjuvant-cdk4-6-inhibitor-optimization","published_at":"2026-03-20T17:38:27+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/myth-vs-medicine-pharmacist-s-perspective-on-adjuvant-cdk4-6-inhibitor-optimization","url":"https://oncologypodcast.simplecast.com/episodes/myth-vs-medicine-pharmacists-perspective-on-adjuvant-cdk4-6-inhibitor-optimization-EWbEJ_1v","duration_seconds":1511,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/myth-vs-medicine-pharmacist-s-perspective-on-adjuvant-cdk4-6-inhibitor-optimization/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/myth-vs-medicine-pharmacist-s-perspective-on-adjuvant-cdk4-6-inhibitor-optimization.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"From ASH 2025 to the Clinic: Global Perspectives on Evolving BTK Therapies in Relapsed/Refractory CLL","slug":"from-ash-2025-to-the-clinic-global-perspectives-on-evolving-btk-therapies-in-relapsed-refractory-cll","published_at":"2026-03-11T16:56:12+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/from-ash-2025-to-the-clinic-global-perspectives-on-evolving-btk-therapies-in-relapsed-refractory-cll","url":"https://oncologypodcast.simplecast.com/episodes/from-ash-2025-to-the-clinic-global-perspectives-on-evolving-btk-therapies-in-relapsed-refractory-cll-dk0fFFb5","duration_seconds":1824,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/from-ash-2025-to-the-clinic-global-perspectives-on-evolving-btk-therapies-in-relapsed-refractory-cll/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/from-ash-2025-to-the-clinic-global-perspectives-on-evolving-btk-therapies-in-relapsed-refractory-cll.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"2025 San Antonio Breast Cancer Symposium Conference Coverage: Highlights Podcast","slug":"2025-san-antonio-breast-cancer-symposium-conference-coverage-highlights-podcast","published_at":"2026-03-09T18:50:16+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/2025-san-antonio-breast-cancer-symposium-conference-coverage-highlights-podcast","url":"https://oncologypodcast.simplecast.com/episodes/2025-sabcs-cf-highlights-_U7HKSWV","duration_seconds":2234,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/2025-san-antonio-breast-cancer-symposium-conference-coverage-highlights-podcast/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/2025-san-antonio-breast-cancer-symposium-conference-coverage-highlights-podcast.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]},{"title":"Advancing KRAS G12C-Targeted Therapies in NSCLC: Current Evidence and Future Directions","slug":"advancing-kras-g12c-targeted-therapies-in-nsclc-current-evidence-and-future-directions","published_at":"2026-03-09T17:28:43+00:00","page_url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/advancing-kras-g12c-targeted-therapies-in-nsclc-current-evidence-and-future-directions","url":"https://oncologypodcast.simplecast.com/episodes/advancing-kras-g12c-targeted-therapies-in-nsclc-current-evidence-and-future-directions-b5W8lj1w","duration_seconds":1004,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/advancing-kras-g12c-targeted-therapies-in-nsclc-current-evidence-and-future-directions/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/advancing-kras-g12c-targeted-therapies-in-nsclc-current-evidence-and-future-directions.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}]}